2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
Recommendations
As issued by the authors
Points to consider (PtC) 1-4: terminology, assay characteristics and reporting practices, to enable more consistent reporting and facilitate translation and collaborations
PtC 5-11: clinical applications for diagnosis and outcome assessments, incl. disease activity, prognosis and prediction of treatment response
Mean level of agreement generally high, mainly for PtC 1-4 and for clinical applications in SLE
Research agenda: harmonisation of assay methodology and clinical validation
Original publication
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. Ann Rheum Dis. Published 1 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →